跳到主要內容

臺灣博碩士論文加值系統

(34.226.244.254) 您好!臺灣時間:2021/08/01 02:24
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:李婉瑜
研究生(外文):Wan-Yu Li
論文名稱:鳳仙花抗幽門螺旋桿菌及其活性成分之研究
論文名稱(外文):Anti-Helicobacter pylori activity of Impatiens balsamina L. and active compounds isolation
指導教授:王苑春
學位類別:碩士
校院名稱:國立中興大學
系所名稱:食品暨應用生物科技學系
學門:醫藥衛生學門
學類:營養學類
論文種類:學術論文
畢業學年度:96
語文別:中文
論文頁數:117
中文關鍵詞:鳳仙花
外文關鍵詞:Impatients balsamina L.
相關次數:
  • 被引用被引用:0
  • 點閱點閱:169
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
幽門螺旋桿菌 (Helicobacter pylori) 被證實與胃癌及腸胃潰瘍有密切相關性。根除幽門螺旋桿菌以抗生素療法為主,長期使用抗生素衍生出幽門螺旋桿菌之抗藥性,造成幽門螺旋桿菌治療失敗的主要原因。本研究探討鳳仙花 (Impatiens balsamin L.) 抗幽門螺旋桿菌活性,並分離其活性成分。
鳳仙花抗幽門螺旋桿菌之結果顯示出,鳳仙花各部位之95 %乙醇萃取物均有相當好之抗幽門螺旋桿菌活性,對11株cagA+及多重抗藥性幽門螺旋桿菌之最低抑菌濃度 (Minimum inhibitory concentration,MICs) 及最低殺菌濃度 (Minimum bactericidal concentration,MBCs) 之範圍均為20-80 μg/mL間。
鳳仙花種殼丙酮萃取物經矽膠管柱層析分離出1個單一成分;種子經脫脂後,其95 %乙醇萃取物經矽膠管柱層析分離出3個單一成分;根/莖/葉95 %乙醇萃取物之正己烷層區分物經矽膠管柱分離出2個單一成分。以上化合物經1H-NMR、13C-NMR、MS、FTIR及UV/VIS圖譜分析之結果,經核磁共振光譜儀等圖譜皆判定為純化合物,其對cagA+及多重抗藥性幽門螺旋桿菌之抑制活性與amoxicillin相似,遠高於metronidazole。
表次……………………………………………Ⅲ
圖次……………………………………………Ⅳ
中文摘要……………………………………………1
英文摘要……………………………………………………3
壹、 前言……………………………………………………………5
貳、 文獻整理 ……………………………………6
一、 幽門螺旋桿菌之生理毒性、致病機轉及根除 ……………6
(一) 幽門螺旋桿菌之發現及生理特徵 ………………6
(二) 幽門螺旋桿菌之毒性特性 ……………………………8
(三) 幽門螺旋桿菌之流行病學 ……………………………11
(四) 幽門螺旋桿菌之傳染途徑 ……………………………11
(五) 幽門螺旋桿菌感染與胃腸疾病 ………………………11
(六) 幽門螺旋桿菌之根除及抗藥性 ………………………11
二、 抑制幽門螺旋桿菌之相關研究………………14
(一) 化學合成藥物 ……………………14
(二) 天然物 ……………………………15
三、 鳳仙花藥材及相關生理活性………………20
(一) 鳳仙花之型態特徵及生長地區……………………………20
(二) 鳳仙花之傳統藥理作用…………………………………21
(三) 鳳仙花之化學成分…………………………21
(四) 鳳仙花之生理活性………………………21
參、 研究目的 ……………………………………………27
肆、 材料與方法 ……………………………………28
一、 材料…………………………………28
(一) 鳳仙花生藥……………………………28
(二) 化學藥劑 …………………………………………28
(三) 儀器設備…………………………………………28
二、 方法……………………………………29
第一部份:鳳仙花95 %乙醇萃取物抗cagA+及抗藥性幽門螺旋桿菌活性之研究………………………………29
(一) 幽門螺旋桿菌來源及培養………………………………29
(二) 鳳仙花萃取物製備………………………………31
(三) 鳳仙花萃取物對幽門螺旋桿菌之抑菌活性…………………32
第二部份:鳳仙花抑制幽門螺旋桿菌成分之研究……………33
(一) 鳳仙花種殼抗幽門螺旋桿菌成分之分離及化學結構定 ………33
(二) 鳳仙花種子抗幽門螺旋桿菌成分之分離及化學結構鑑定……36
(三) 鳳仙花根/莖/葉抗幽門螺旋桿菌成分之分離及化學結構鑑定…37
(四) 化合物抗幽門螺旋桿菌活性測定………………40
伍、 結果與討論…………………………………41
第一部份:鳳仙花95 %乙醇萃取物抗cagA+及抗藥性幽門螺旋桿菌活性之研究…………………………………41
一、 鳳仙花各部位百分比及萃取率……………41
二、 最小抑菌濃度及最小殺菌濃度……………41
第二部份:鳳仙花抑制幽門螺旋桿菌成分之研究………………46
一、 鳳仙花種殼抗幽門螺旋桿菌成分之分離及化學結構定…46
(一) 鳳仙花種殼抗幽門螺旋桿菌成分之分離……………48
(二) 化學結構鑑定……………………………………48
二、 鳳仙花種子抗幽門螺旋桿菌成分之分離及化學結構鑑定…60
(一) 鳳仙花種子抗幽門螺旋桿菌成分之離 …………………60
(二) 化學結構定……………………………………………64
三、 鳳仙花根/莖/葉抗幽門螺旋桿菌成分之分離及化學結構定…70
(一) 正己烷層區分物抗幽門螺旋桿菌分離……………………70
(二) 化學結構定……………………………………73
(三) 水層區分物抗幽門螺旋桿菌分離………………89
四、化合物抗幽門螺旋桿菌活性測定………………………91
陸、 結論…………………………………107
柒、 參考文獻………………………………………108
邱年永、張光雄 原色台灣藥用植物圖鑑 (一)。南天書局。台北。P.114。1998。
劉永豐、嚴助成、何愛生:幽門螺旋桿菌的治病因子。國防醫學。22,291-294。1996。
譚健民 幽門螺旋桿菌導致胃黏膜傷害的免疫致病機轉。台灣醫界。51 (1)。1999。
Alarcon, T., Domingo, D., and Lopez, B. M. Antibiotic resistance problems with Helicobacter pylori. Int. J. Antimicrob. Agents. 12 : 19-26 (1999).
Ando, R., Kawamura, M., and Chiba, N. 3-(arylacetylamino) -N- methylbenzamides: a novel class of selective anti-Helicobacter pylori agents. J. Med. Chem. 44 : 4468-4474 (2001).
Bardhan, P. K. Epidemiological features of Helicobacter pylori infection in developing countries. Clin. Infect. Dis. 25 : 973-978 (1997).
Bhamarapravati, S., Juthapruth, S., Mahachai, W., and Mahady, G. Antibacterial activity of Boesenbergia rotunda (L.) Mansf. and Myristica fragrans Houtt. against Helicobacter pylori. Songklanakarin J. Sci. Technol. 28 : 157-163 (2006).
Blecker, V., Mckeitham, T. W., Hant, J., and Kirschner, B. S. Resolution of Helicobacter pylori associated gastric lympo-proliferative disease in a child. Gastroenterology. 109 : 973-977 (1995).
Bruce, M. G., Bruce, D. L., Mcmahon, B. J., Hennessy, T. W., Reasonover, A., Morris, J., Hurlburt, D. A., Peters, H., Sacco, F., Martinez, P., Swenson, M., Berg, D. E., Parka, D., and Parkinson, A. J. Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. Helicobacter. 11 : 581-588 (2006).
Chimenti, F., Bizzari, B., Manna, F., Bolasco, A., Secci, D., Chimenti, P., Granese, A., Rivanera, D., Lilli, D., Scaltrito, M. M., and Brenciaglia, M. I. Synthesis and in vitro selective anti-Helicobacter pylori avtivity of pyrazoline derivatives. Bioorganic and Medicinal Chemistry Letters. 15: 603-607 (2005).
Chimenti, F., Bizzari, B., Manna, F., Bolasco, A., Secci, D., Chimenti, P., Carradori, S. Granese, A., Rivanera, D., Lilli, D., Scaltrito, M. M., and Brenciaglia, M. I. Synthesis and in vitro selective anti-Helicobacter pylori activity of N-substituted-2-oxo-2H-1-benzopyran-3-carboxamides. Eur. J. Med. Chem. 41 : 208-212 (2006).
Chimenti, F., Bizzarri, B., Bolasco, A., Secci, D., Chimenti, P., Carradori, S., Granese, A., Rivanera, D., Lilli, D., Zicari, A., Scaltrito, M. M., and Sisto, F. A novel class of selective anti-Helicobacter pylori agents 2-oxo-2H-chromene-3-carboxaminde derivatives. Bioorganic and Medicinal Chemistry Letters. 17 : 3065-3071 (2007).
Covacci, A., Telford, J. L., Giudice, G. D., Parsonnet, J., and Rappuoli, R. Helicobacter pylori virulence and genetic geography. Science. 284 : 1328-1333 (1999).
Ding, Z. S., Jiang, F. S., Chen, N. P., Lv, G. Y., and Zhu, C. G. Isolation and identification of an anti-tumor component from leaves of Impatiens balsamina. Molecules. 13 : 220-229 (2008).
Dunn, B. E., Cohen, H., and Blaser, M. J. Helicobacter pylori. Clin. Microbiol. Rev. 10 : 720-41 (1997).
Duck, W. M., Sobel, J., Pruckler, J. M., Song, Q., Swerdlow, D., Friedman, C., Sulka, A., Swaminathan, B., Taylor, T., Hoekstra, M., Griffin, P., Smoot, D., Peek, R., Metz, D. C., Bloom, P. B., Goldschmid, S., Parsonnet, J., Triadafilopoulos, G., Perez-Perez, G.I., Vakil, N., Ernst, P., Czinn, S., Dunne, D., and Gold, B. D. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis. 10 : 1088-1094 (2004).
Egi, Y., Ito, M., Tanaka, S., Imagawa, S., Takata, S., Yoshihara, M., Haruma, K., and Chayama, K. Role of Helicobacter pylori infection and chronic inflammation in gastric cancer in the cardia. Jpn. J. Clin. Oncol. 37 : 365-369 (2007).
Fallahi, G. H., and Maleknejad, S. Helicobacter pylori culture antimicrobial resistance in Iran. Indian Journal of Pediatrics. 74: 127-130 (2007).
Fukai, T., Marumo, A., Kaitou, K., Kanda, T., Terada, S., and Nomura, T. Anti-Helicobacter pylori flavonoids from licorice extract. Life sci. 71: 1449-1463 (2002).
Gadhi, C. A., Benharref, A., Jana, M., and Lozniewski, A. Anti-Helicobacter pylori activity of Aristolochia paucinervis pomel extract. J. Ethnopharmacol. 75 : 203-205 (2001).
Gatti L. L., Fagundes e Souza E. K., Leite, K. R., Bastos, E. L., Vicentini, L. R., Silva, L. C., Smith, M. A., and Payão, S. L. CagA vacA alelles and babA2 genotypes of Helicobacter pylori associated with gastric disease in Brazilian adult patients. Diagn. Microbiol. Infect. Dis. 51 : 231-235 (2005).
Gerhard, M., Rad, R., Prinz, C., and Naumann, M. Pathogenesis of Helicobacter pylori infection. Helicobacter.7 : 17-23 (2002).
Gerhard, M., Lehn, N., Neumayer, N., Boren, T., Rad, R., Schepp, W., Miechlke, S., Classen, M., and Prinz, C. Clinical relevance of Helicobacter pylori gene for blood-group antigen-binding adhesion. Proc. Natl. Acad. Sci.USA. 96 : 12778-12783 (1999).
Gisbert, J. P., and Pajares, J. M. Helicobacter pylori therapy: first-line options and rescue regimen. Dig Dis. 19 : 134-143 (2001).
Goodwin, C. S., Armstrong, J. A., Chilvers, T., Peters, M., Collins, M. D., Sly, L., McConnell., and Harper, W. E. S. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter mustelae comb. nov., respectively. Int. J. Syst. Bacterial. 39: 397-405 (1989).
Handa, O., Naito, Y., and Yoshikawa, T. CagA protein Helicobacter pylori: A hijacker of gastric epithelial cell signaling. Biochem. Pharmacol. 10: 1-19 (2006).
Haque, T. S., Tadesse, S., Marcinkeviciene, J., Rogers, M. J., Sizemore, C., Kopcho, L. M., Amsler, K., Ecret, L. D., Zhan, D. L., Hobbs, F., Slee, A., Trainor, G. L., Stern, A. M., Copeland, R. A., and Combs, A. P. Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate drhydrogenase. J. Med. Chem.45 : 4669-4678 (2002).
Hatakeyama, M., and Higashi, H. Helicobacter pylori CagA: a new paradigm for bacterical carcinogenesis. Cancer Science. 96: 835-843 (2005).
Hoffman, J. S.C., and David, R. Treatment of Helicobacter pylori. Curr. Opin. Gastroenterol.17 : 30 (2001).
Hu, C. T., Wu, C. C., Lin, C. Y., Cheng, C. C., Su, S. C., and Tseng, Y. H. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. Gastroenterology. 22 : 720-723 (2007).
Ishiguro, K., Fukumoto, H., Osada, S., Isoi, K., and Semma M. A practical, reproducible measre of measure of murine anaphylaxis: blood pressure monitoring of anaphylaxis and effect of Impatiens balsamina. Phytother. Res. 8 : 301-304 (1994).
Ishiguro, K., Isoi, K., Yamaki, M., and Fukumoto, H. Antianaphylactic effects of the principal compounds from the white petals of Impatiens balsamina L. Phytother. Res.10 : 202-206 (1996).
Ishiguro, K., and Fukumoto, H. A practical and speedy screening method for murine anaphylaxis: on the antianaphylactic effect of Impatiens balsamina L. Phytother. Res.11 : 48-50 (1997).
Ishiguro, K., and Oku, H. Antipruritic effect of flavonol and 1,4-Naphthoquinone derivatives from Impatiens balsamina L. Phytother. Res. 11 : 343-347 (1997).
Ishiguro, K, Oku, H., and Ohira, Y. Antipruritic dinaphthofuran -7,12-dione derivatives from the pericarp of Impatiens balsamina L. J. Nat. Prod. 61: 1126-1129 (1998).
Ishiguro, K., and Oku, H. Antipruritic and antidermatitic effect of extract and compounds of Impatiens balsamina L. in atopic dermatitis model NC mice. Phytother. Res. 15 : 506-510 (2001).
Ishiguro, K., and Oku, H. Cyclooxygenase-2 inhibitory 1,4-naphthoquinones from Impatiens balsamina L. Biol. Pharm. Bull. 25: 658-660 (2002).
Ishiguro, k., Oku, H., and Kato, T. Antipruritic effect of 1,4-naphthoquinones and related compounds. Biol. Pharm. Bull. 25: 137-139 (2002).
Kalach N. Bergeret, M., Benhamou, P. H., Dupont, C., and Raymond, J. High levels of resistance to Metronidazole and Clarithromycin in Helicobacter pylori strains in children. J. Clin. Microbial. 39: 394-397 (2001).
Katsura, Y., Tomishi, T., Inoue, Y., Sakane, K., and Matsumoto, Y. Anti-Helicobacter pylori agents. 1. 2-(alkylguanidino) -4- furylthiazoles and related compounds. J. Med. Chem. 40 : 2462-2465 (1997).
Katsura, Y., Nishino, S., Tomishi, T., Sakane, K., Matsumoto, Y., Ishikawa, H., and Takasugi.Anti-Helicobacter pylori agents. 2. structure activity relationships in a new series of 2-alkylguanidino- 4-furylthiazoles. Bioorganic and Medicinal Chemistry Letters. 8 : 1307-1312 (1998).
Kim, J. M., Kim, J. S., Kim, N., Kim, G. S., Jung, H. C., and Song, I. S. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int. J. Antimicrob. Agents. 28 : 6-13 (2006).
Kobayashi, I., Muraoka, H., Hasegawa, M., Saika, T., Nishida, M., Kawamura, M., and Ando, R. In vitro anti-Helicobacter pylori activity of BAS-118, a new benzamide derivative. J. Antimicrob. Chemother. 50 : 129-132 (2002).
Leo, M. D., Tommasi, N. D., Sanogo, R., Angelo, V. D., Germano, M. P., Bisignano, G., and Braca, A. Triterpenoid saponins from Pteleopsis suberosa stem bark. Phytochemistry. 67 : 2623-2629 (2006).
Li, Y., Xu, C., Zhang., Q., Liu, J. Y., and Tan, R. X. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J. Ethnopharmacol. 98 : 329-333 (2005).
Li, X. B., Ge, Z. Z., Chen, X. Y., and Liu, W. Z. Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis. Braz. J. Med. Biol. Res. 1-6 (2007).
Lin, J. T., Wang, J. T., Wang, T. H., Wu, M, S., Lee, T. K., and Chen, C, J. Helicobacter pylori infection in a randomly selected population, healthy volunteers, and patients with gastric ulcer and gastric adenocarcinoma. A seroprevalence study in Taiwan. Scand J. Gastroenterol. 28 : 1067-72 (1993).
Lobstein, A., Brenne, X., Feist, E., Metz, N., Weniger, B., and Anton, R. Quantitative determination of naphthoquinones of impatiens species. Phytochem. Anal. 12 : 202-205 (2001).
Malaty, H-M. Epidemiology of Helicobacter pylori infection. Best Practice & Research Clinical Gastroenterology. 21 : 205-214 (2007).
Marshall, B. J., Royce, H., Annear, D. I., Goodwin, C. S., Pearman, J. W., Warren, J. R., and Armstrong, J. A. Oringinal isolation of Campylobacter pyloridis from human gastric mucosa. Microbiol. Lett. 25 : 83-88 (1984).
Megraud, F., Brassens-Rabbe, M. P., Denis, F., Belbouri, A., and Hoa, D. Q. Seropidemiology of Campylobacter pylori infection in various populations. J. Clin. Microbiol. 27 : 1870-1873 (1989).
Mou, S. M. The relationship between Helicobacter pylori infection and peptic ulcer disease. Prim. Care Update Ob Gyns. 5 : 229-232 (1998).
Nam, G., Kang, T. W., Shin, J. H., and Choi, K. Design, synthesis, and anti-Helicobacter pylori activity of erythromycin A (E)-9-oxime ether derivatives. Bioorganic and Medicinal Chemistry Letters. 16 : 569-572 (2006).
Ndip, R. N., Tarkang, M. A. E., Mbullah, S. M., Luma, H. N., Malongue, A., Nidp, L. M., and Nyongbela, K. In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. J. Ethnopharmacol. 114 : 452-457 (2007).
Nikolic, D., Habibi-Goudarzi, S., Corley, D. G., Gafner, S., Pezzuto, J. M., and van Breemen, R. B. Evaluation of cyclooxygenase-2 inhibitors using pulsed ultrafiltration mass spectrometry. Anal Chem. 72 : 3853-3859 (2000).
Nostro, A., Cellini, L., Bartolomeo, S. D., Campli, E. D., Grande, R., Cannatelli, M. A., Marzio, L., and Alonzo, V. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother. Res. 19 : 198-202 (2005).
Ochi, T., Shibata, H., Higuti, T., Kodama, K., Kusumi, T., and Takaishi, Y. Anti-Helicobacter pylori compounds from Santalum album. J. Nat. Prod. 68 : 819-824 (2005).
Ohsaki, A., Takashima, J., Chiba, N., and Kawamura, M. Microanalysis of a selective potent anti-Helicobacter pylori compound in a brazilian medicinal plant, Myroxylon peruiferum and the activity of anglogues. Bioorganic and Medicinal Chemistry Letters. 9 : 1109-1112 (1999).
Oku, H., and Ishiguro, K. Screening method for PAF antagonist substances: on the phenolic compounds from Impatiens balsamina L. Phytother. Res. 13 : 521-525 (1999).
Park, B- S., Lee, H-K., Lee, S-E., Piao, X-L., Takeoka, G. R., Wong, R.Y., Ahn, Y-J., and Kim, J-H. Antibacteral activity of Tabebuia impetiginosa Martius ex DC ( Taheeho ) against Helicobacter pylori. J. Ethnopharmacol. 105 : 255-262 (2006).
Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin. 47 : 5–27 (1997).
Panichayupakaranat, P., Noguchi, H., Eknamkul D. W., and Sankawa U.Naphthoquinones and coumarins from Impatiens balsamina L. root cultures. Phytochemistry. 40 : 1141-1143 (1995).
Ruegg, T., Calderon, A. I., Queiroz, E. F., Solis, P. N., Marston, A., Rivas, F., Ortega-Barria, E., Hostettmann, K., and Gupta, M. P. 3-Farnesyl-2-hydroxybenzoic acid is new anti-Helicobacter pylori compound from Piper multiplnervium. J. Ethnopharmacol. 103 : 461-467 (2006).
Rauws, E. A. J., and Tytgat, G. N. J. 7 Helicobacter pylori in duodenal and gastric ulcer disease. Billieres Clin. Gastroenterol. 9 : 529-547 (1995).
Smoot, D. T., Mobley, H. L-H., Chippendale, G. R., Lewison, J. F., and Resau, J. H. Helicobacter pylori urease activity is toxic to human gastric epithelial cells. Infect. Immun. 58 : 1992-1994 (1990).
Sorba, G., Bertinaria, M., Stilo, A. D., Gasco, A., Scaltrito, M. M., Brenciaglia, M. I., and Dubini, F. Anti-Helicobacter pylori agents endowed with H2-antagonist properties. Bioorganic and Medicinal Chemistry Letters. 11 : 403-406 (2001).
Spengler, G., Molnar, A., and Klausz, G. Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin susceptible and-resistant Helicobacter pylori. Int. J. Antimicrob. Agents. 23 : 631-633 (2004).
Suerbaum, S., and Josenhans, C. Virulence factors of Helicobacter pylori: implications for vaccine development. Mol. Med. Today (1999).
Tailor, R. H., Acland, D. P., Attenborough, S., Cammue, B. P. A., Evans, I. J., Osborn, R. W., Ray, J. A., Rees, S. B., and Broekaert, W. F. A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina L. is derived from a single precursor protein. J. Biol. Chem. 272 : 24480-24487 (1997).
Thevissen, K., Francois, I-E. J. A., Sijtsma, L., Amerongen, A. V., Schaaper, W-M. M., Meloen, R., and Cammue, B-P. A . Antifungal activity of synthetic peptides derived from Impatiens balsamina L. antimicrobial peptides Ib-AMP1 and Ib-AMP4. Peptides. 26 : 1113-1119 (2005).
Tummuru, M. K., Cover, T. L., and Blaser, M. J. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect. Immun. 61 : 1799-1809 (1993).
Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., and Sasaki, N. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345 : 784-789 (2001).
Ustun, O., Ozcelik, B., Akyon, Y., Abbasoglu, U., and Yesilada, E. Flavonoids with anti-Helicobacter pylori activity from Cistus laurifolius leaves. J. Ethnopharmacol. 108 : 457-461 (2006).
Wayman, J., Forman, D., and Griffin, S. M. Monitoring the changing pattern of esophago -gastric cancer: data from a UK regional cancer registry. Cancer Causes Control 12 : 943–49 (2001).
Wolle, K., Leodolter, A., Malfertheiner, P., and Konig, W. Antibiotic susceptibility of Helicobacter pylori in Germany : stable primary resistance from 1995 to 2000. J. Med. Microbiol. 51 : 705-709 (2002).
Yee, Y-K., and Koo, M. W-L. Anti-Helicobacter pylori activity of Chinese tea: in vitro study. Aliment. Pharmacol. Ther. 14 : 635-638 (2000).
Yesilada, E., Gurbuz, I., and Shibata, H. Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity. J. Ethnopharmacol. 66 : 289-293 (1999).
Yin, S., Fan, C-Q., Dong, L., and Yue, J-M. Psoracorylifols A-E, five novel compounds with activity against Helicobacter pylori from seed of Psoralea corylifolia. Tetrahedron. 62 : 2569-2575 (2006).
Yoshida, Y., Barrett, D., Azami, H., Morinaga, C., Matsumoto, Y., and Takasugi, H. Discovery of a novel benzyloxyisoquinoline derivative with potent anti-Helicobacter pylori activity. Bioorganic and Medicinal Chemistry Letters. 8 : 1897-1902 (1998).
Yoshida, Y., Barrett, D., Azami, H., Morinaga, C., Matsumoto, S., Matsumoto, Y., and Takasugi, H. Studies on anti-Helicobacter pylori agents. Part 1: Benzyloxyisoquinoline derivatives. Bioorganic and Medicinal Chemistry. 7 : 2647-2666 (1999).
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top